The T-cell immunotherapy Orca-T has gained FDA approval in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) ...
Landau, MD, discusses results from a trial of the investigational CAR T-cell therapy NXC-201 in relapsed/refractory AL ...
Ziftomenib combinations show promising frontline AML results, expanding trials with chemo and targeted partners; phase 3 aims ...
The US FDA has issued a complete response letter (CRL) for gallium Ga 68 edotreotide (LNTH-2501), a positron emission tomography (PET) diagnostic kit developed by Lantheus Holdings for localizing ...
Explore how genomics, comorbidities, and patient goals steer frontline CLL therapy, from fixed-duration venetoclax regimens to continuous BTK inhibitors. In an interview with Targeted Oncology at the ...
Dr. Monty Pal introduces the program by outlining the evolving treatment landscape for advanced renal cell carcinoma (RCC) ...
NCCN now recognizes personalized, tumor-informed ctDNA-MRD as a prognostic and predictive biomarker in MIBC, extending ...
Daniel Ermann, MD, discusses how clinical and real-world data drive his discussions with older CLL patients regarding ...
Conversion from MRD negativity to positivity during maintenance is substantially lower with the quadruplet, and ...
A 74-year-old man with an active lifestyle and no family history of prostate cancer presented with mild urinary hesitancy and ...
Daniel Ermann, MD, discusses treatment considerations with newly diagnosed older/elderly patients with chronic lymphocytic ...
Daniel Ermann, MD, discusses his approach to treatment sequencing in patients with chronic lymphocytic leukemia who aged 80 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results